What Mammotome does

Mammotome, operating through its legal entity Devicor Medical Products, Inc., is a global medical device company focused on breast care diagnostics and surgical treatment, headquartered in Cincinnati, Ohio with manufacturing in Tijuana, Mexico and a European hub in Quickborn, Germany. Founded in 1992, the company pioneered vacuum-assisted breast biopsy and now distributes products in more than 60 countries across 9 locations with 550+ dedicated associates. Mammotome has been a subsidiary of Danaher Corporation since 2014, gaining access to the Danaher Business System and shared commercial infrastructure. The company reports that more than 11 million women have undergone procedures using its devices over its 30-year history.

Mammotome's portfolio spans two integrated stages of the breast cancer care pathway: biopsy and local surgical treatment. The biopsy franchise includes the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy System (positioned as the industry's first in-room MR-guided system), the Revolve family (EX, U/S, and ST variants for excision, ultrasound, and stereotactic procedures respectively), the Mammotome Elite, and the DualCore dual-stage core biopsy system. The biopsy site marker portfolio covers HydroMARK and HydroMARK Plus (hydrogel-based with titanium wing shapes), LumiMARK (nitinol shapes), MammoMARK (collagen), MammoSTAR and BiomarC (non-metal alternatives). The surgical franchise includes the Neoprobe Gamma Detection System for sentinel lymph node mapping and the Pintuition surgical marker navigation system distributed exclusively from Sirius Medical in five countries. Mammotome also offers specimen radiography systems (Confirm SRS, XPERT 40 SRS).

Mammotome generates revenue primarily through hardware sales of capital equipment paired with consumable disposables and biopsy site markers, sold via a global enterprise field sales force and regional distribution partners. Pricing is not publicly disclosed and follows a contact-based quoting model directed at radiologists, breast surgeons, and oncologists in hospitals and cancer care centers. Marketing channels center on professional conferences (Society of Breast Imaging Symposium, European Society of Radiology), clinical education programs, and direct sales outreach. The company is privately held under Danaher, with no public ticker.

Name

Mammotome

Legal name

Devicor Medical Products, Inc.

Website

https://mammotome.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Mammotome is a Danaher-owned medical device company specializing in breast biopsy systems, biopsy site markers, and surgical localization tools (including gamma detection and GPS-guided navigation), sold to radiologists, breast surgeons, and oncology centers in 60+ countries.

Ownership category

akta.pro rank

Product category

Breast Biopsy Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Mammography & Breast Imaging Systems (HLAHABAF)

Keywords

• Breast biopsy systems
• Biopsy site markers
• Surgical navigation devices
• Minimally invasive diagnostics
• Medical device manufacturing

Headquarters

HQ city

Cincinnati

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Medical Device Sales: Mammotome generates revenue through the sale of medical devices including breast biopsy systems, biopsy markers, gamma detection systems, and surgical navigation equipment. Products are sold through direct sales, distribution partners, and at conferences.
2. Disposable Components and Accessories: Sale of disposable probes, applicators, and accessories for biopsy procedures. The Mammotome Elite system consists of reusable charging base and holster with disposable one-time use probes.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Mammotome (legal entity: Devicor Medical Products, Inc.) designs, manufactures, and distributes minimally invasive breast biopsy systems, biopsy site markers, and breast surgical navigation devices. Its product portfolio includes vacuum-assisted biopsy systems, stereotactic biopsy systems, core needle biopsy instruments, hydrogel and metallic biopsy site markers, gamma detection probes, and wire-free surgical localization systems used by radiologists, breast surgeons, and pathology labs for breast cancer diagnosis and treatment.

Product overview

Mammotome is a global medical technology company specializing in breast care diagnostics and surgical solutions, operating as a subsidiary of Danaher Corporation. The company offers a comprehensive portfolio of products covering two integrated main steps in the breast cancer treatment pathway: breast biopsy and local surgical treatments. The product portfolio includes the Mammotome Prima™ MR System (industry's first in-room MR-guided biopsy system), the Mammotome Revolve™ family of vacuum-assisted breast biopsy systems (Revolve™ EX for lesion excision, Revolve™ U/S for ultrasound guidance, and Revolve™ ST for stereotactic procedures), the Mammotome® Elite System and DualCore™ System for core biopsies, the Neoprobe® Gamma Detection System for sentinel lymph node procedures, and the Pintuition® System for surgical marker navigation. The company also offers the most comprehensive portfolio of breast biopsy site markers including HydroMARK™ Plus (with hydrogel technology and titanium wing shapes), HydroMARK™ (original hydrogel-based marker), LumiMARK™ (nitinol shapes), MammoMARK® (collagen-based), MammoSTAR® and BiomarC® (non-metal alternatives), along with specimen radiography systems (Mammotome Confirm™ SRS and XPERT® 40 SRS). Products are sold in over 60 countries worldwide with headquarters in Cincinnati, Ohio.

Differentiator

Problem solved

Functional benefit

Brands

• Mammotome Prima: MR Dual Vacuum-Assisted Breast Biopsy System - the industry's first in-room system designed for use within the MRI scanner room.
• Mammotome Revolve
• Mammotome Revolve EX
• Mammotome Elite
• Mammotome DualCore
• HydroMARK
• HydroMARK Plus
• LumiMARK
• MammoMARK
• MammoSTAR
• BiomarC
• Pintuition
• Neoprobe GDS

Products and services

• Mammotome Elite

Named customers4 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

Feature4 records

Partnerships

One partnership is on record.

• Sirius MedicalcoreChannel Partner/ Reseller/ Distributor · 10 March 2026Mammotome serves as exclusive distributor for Sirius Medical's Pintuition® System in the United States, Germany, Italy, Poland, and Canada. The Pintuition® System provides surgical marker navigation using GPSDetect® software and TargetLOC® technology for millimeter precision tumor localization. This partnership expands Mammotome's breast care portfolio with innovative navigation technology.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Hologic: Hologic is the dominant breast health incumbent with a vertically integrated franchise spanning 3D mammography (Dimensions), vacuum-assisted biopsy (ATEC), biopsy markers (BioZorb), and breast surgery. Mammotome competes head-to-head with Hologic in stereotactic biopsy, biopsy markers, and surgical localization, and Hologic's bundled procurement model is a primary competitive threat to Mammotome's hospital accounts.
• BD (Becton Dickinson): BD is a major medical device manufacturer with significant breast biopsy and diagnostic product lines (BD MaxCore, BD Achieve), plus biopsy site markers. The company competes with Mammotome in core needle biopsy, marker placement, and women's health surgical solutions across hospital and outpatient settings.
• Merit Medical: Merit Medical acquired Cianna Medical and markets the SCOUT radar localization system, which competes directly with Mammotome's Pintuition surgical marker navigation system in breast surgery. Merit is a meaningful peer for breast surgical guidance and also overlaps in interventional oncology medical devices.
• Cook Medical: Cook Medical manufactures breast biopsy needles, localization wires, and related interventional radiology products that compete with Mammotome's vacuum-assisted biopsy systems and surgical localization portfolio. Cook is a long-established player in breast and soft tissue biopsy devices.

Emerging players

• Endomag: Endomag develops magnetic surgical guidance technologies (Magseed marker, Magtrace lymphatic tracer) used in breast cancer surgery as an alternative to radioactive seed and GPS-based localization. Endomag is a direct emerging competitor to Mammotome's Pintuition and offers a non-radioactive, non-magnetic alternative proposition in the same surgical localization category.
• Sirius Medical: Sirius Medical is the inventor and manufacturer of the Pintuition surgical marker navigation system that Mammotome distributes exclusively in the US, Germany, Italy, Poland, and Canada. Although a distribution partner, Sirius Medical is a strategic peer because it controls the underlying GPSDetect and TargetLOC technology and could evolve into a direct competitor if the partnership changes.

Broad incumbents

• Medtronic: Medtronic is a global medtech conglomerate with overlapping presence in surgical oncology, biopsy instrumentation, and women's health through its Surgical Innovations and early lung/breast diagnostic portfolios. While not a direct breast biopsy competitor, Medtronic represents the kind of diversified incumbent that consolidates hospital purchasing decisions and could encroach on Mammotome's niche.
• Stryker: Stryker is a broad medical device incumbent with a growing presence in surgical visualization, navigation, and oncology surgery. While not a direct breast biopsy competitor, Stryker competes in adjacent surgical navigation categories (orthopedics, neurosurgery, ENT) where technology platforms could be extended into breast surgery, posing a long-term competitive risk to Mammotome's Pintuition franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/mammotome
• LinkedInlinkedin.com/company/1113427

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mammotome